Semaglutide as an Inhibitor: What It Does and Doesn't Block

Step 1: What GLP-1 receptor agonism actually means

Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases after you eat. It signals to the pancreas, the brain and the stomach that food has arrived. Semaglutide is a synthetic molecule that mimics this hormone closely enough to bind to the same receptors and trigger the same chain of events. That binding action is activation, not inhibition, an agonist turns a switch on; an inhibitor turns one off.

The confusion often arises because several popular diabetes medicines are genuine inhibitors: SGLT2 inhibitors block a transporter in the kidney that would otherwise reabsorb glucose, and DPP-4 inhibitors block an enzyme that breaks down natural GLP-1. Semaglutide takes a different route entirely. Rather than protecting the body's own GLP-1 from degradation, it supplies a longer-acting version of the signal directly. The NHS medicines page on semaglutide explains this mechanism clearly if you want to read the patient-level detail.

Worth noting: because semaglutide is engineered to resist the enzyme (DPP-4) that rapidly clears natural GLP-1, it stays active for roughly a week, which is why Wegovy is a once-weekly injection rather than a daily tablet. The Wegovy overview at nume covers the injection schedule and what to expect from the first pen.

Step 2: The three places semaglutide acts, and the effects that follow

Once semaglutide binds its receptors, the physiological sequence runs roughly like this. First, in the pancreas, it stimulates insulin release in a glucose-dependent way, which means the signal is stronger when blood sugar is elevated and weaker when it is already low, a built-in safety feature. Second, it suppresses glucagon, the hormone that would otherwise tell the liver to release stored glucose. Third, and most relevant for weight management, it acts on appetite-regulating centres in the brain and slows the rate at which the stomach empties.

The practical result is that food feels more satisfying sooner and stays with you longer. People on semaglutide typically find that portion sizes fall naturally and the urge to snack between meals decreases. The STEP 1 trial (a landmark randomised controlled trial published in the New England Journal of Medicine) found an average body-weight reduction of around 15% over 68 weeks among adults with obesity who used 2.4mg semaglutide weekly alongside lifestyle changes. That figure comes from a specific trial population; individual results vary and a prescriber assesses whether treatment is appropriate for you.

One practical question our prescribers hear regularly: does any other medicine the person takes interact with semaglutide through this mechanism? Gastric slowing can affect how quickly other oral medicines absorb, which is one reason the consultation covers your full medication list.

Step 3: Where semaglutide sits among UK-licensed weight-loss medicines

It helps to place semaglutide in the wider landscape of weight-management pharmacotherapy, because the inhibitor/agonist distinction has real clinical consequences. Orlistat is a genuine inhibitor, it blocks pancreatic lipase, reducing fat absorption from the gut. Tirzepatide (Mounjaro) is a dual agonist at both the GIP and GLP-1 receptors. Semaglutide (Wegovy) is a single GLP-1 agonist. None of these medicines overlaps mechanistically with SGLT2 inhibitors or DPP-4 inhibitors.

If you have read about the differences between Wegovy and SGLT2 inhibitors, you will know that combining these classes is a clinical question, not a patient decision, drug interactions, contraindications and individual health context all play a role. For anyone curious about how the cost of treatment compares across private providers, the Wegovy price comparison page puts UK private pricing in context.

NICE has appraised semaglutide for weight management (guidance TA875) and sets out eligibility criteria; those criteria are narrower on the NHS than the licensed indication, which covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews the whole picture at consultation, BMI alone never settles the question.

Step 4: What this means for getting started safely

Because semaglutide works through a specific receptor pathway rather than by suppressing an enzyme, the side-effect profile is dominated by gastrointestinal effects: nausea, loose stools, constipation, reflux and fatigue are the most commonly reported, especially in the first weeks of treatment or after a dose increase. These typically ease as the body adjusts, and if you want detail on what to expect at the beginning of treatment, our guide to semaglutide 1mg covers the starting dose in full. Severe, persistent abdominal pain that radiates to the back warrants prompt medical attention, as pancreatitis (though uncommon) is a recognised risk with GLP-1 medicines.

Semaglutide is not appropriate during pregnancy, while breastfeeding, or for anyone trying to conceive; it is not licensed for people under 18. There are also specific considerations around oral contraceptives and HRT, topics covered in the consultation process, and our guide to semaglutide 2mg explains what the dose escalation to that level involves.

If you are exploring semaglutide as a treatment option and want to understand what an assessment involves, our prescribers review every consultation the same day it is submitted, a real clinician, not automated scoring software, reads your answers. Once approved, your treatment is dispatched the same day (for orders placed before 12pm) and arrives via DPD the next working day in plain, unbranded packaging, so nothing about the box announces what is inside. If you have questions before starting, the FAQs cover the most common ones, or you can get in touch directly.

For a full picture of the weight-loss medicines available through nume (sorry, through our treatments page) all the relevant options and eligibility guidance are in one place. Starting with an accurate understanding of how semaglutide actually works, rather than the shorthand that circulates online, puts you in a much better position to have a useful conversation with a prescriber.